Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
C-Rad AB Class B ( ($SE:CRAD.B) ) has provided an update.
C-RAD has secured a significant order from Krajská Nemocnice Hospital in Liberec, Czech Republic, valued at 10 MSEK, to supply their advanced SGRT systems including Catalyst+™ HD and Sentinel™ 4DCT. This order enhances C-RAD’s presence in the Czech market, reinforcing their position as a trusted provider of radiation therapy solutions and paving the way for future collaborations in the region.
The most recent analyst rating on ($SE:CRAD.B) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on C-Rad AB Class B stock, see the SE:CRAD.B Stock Forecast page.
More about C-Rad AB Class B
C-RAD is a global leader in Surface Guided Radiation Therapy (SGRT), developing surface-guided imaging solutions for radiation therapy. Their technology allows for highly accurate dose delivery to tumors while protecting healthy tissue, utilizing high-speed 3D cameras and augmented reality to ensure patient safety and comfort. C-RAD is listed on NASDAQ Stockholm.
Average Trading Volume: 40,581
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.01B
See more data about CRAD.B stock on TipRanks’ Stock Analysis page.